Compounded peptide comparisons and education.
Long-form articles for the patient deciding between two molecules, two carriers, or two clinical pathways. Each post is reviewed by Dr. Jonathan Snipes, MD (NPI 1821250077) and cites primary clinical literature inline.
Weight loss
7 min read
Compounded tirzepatide vs Mounjaro vs Zepbound: a 2026 comparison
Same molecule. Different dosing protocols. Different price. The honest read on what differs and what does not when you compare compounded tirzepatide to the two branded versions.
Read the article →
Weight loss
8 min read
Semaglutide vs tirzepatide for weight loss: which one wins in 2026
Tirzepatide produced 20.2 percent mean loss versus semaglutide's 13.7 percent in head-to-head trial data. Why the dual-receptor mechanism matters and where semaglutide is still the right call.
Read the article →
Growth hormone
6 min read
Tesamorelin vs sermorelin: which growth hormone peptide is right for you
Sermorelin is the gentler short-acting option. Tesamorelin is FDA-approved as Egrifta and has the strongest visceral-adiposity evidence. The case for each, side-by-side.
Read the article →
Quality
6 min read
How to read a peptide Certificate of Analysis (COA)
What every field on a real Eagle Analytical lab report means: ScanRDI sterility, USP <85> endotoxin, USP <621> potency, lot numbers, BUDs, and how to verify your shipment matches a published report.
Read the article →
Formulation
5 min read
Glycine vs B-12 carrier: which compounded GLP-1 formulation is right
Same tirzepatide. Same semaglutide. Different carrier. When B-12 sensitivity, MTHFR variants, or histamine reactions make the glycine formulation the right call, and why it costs more to compound.
Read the article →
vs. competitor comparisons
Verified pricing
Looking for procedural guides instead?